SCHEMBL15969259

SCHEMBL15969259

O=C(NCCCOc1ccccc1C(F)(F)F)c1c(O)c(=O)[nH]c2ccc(OC(F)(F)F)cc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 1/20 0.42
HDAC1 Q13547 2/20 0.41
HDAC2 Q92769 1/20 0.41
MCHR1 Q99705 1/20 0.41
HDAC3 O15379 1/20 0.40
KMT2A Q03164 5/20 0.40
MEN1 O00255 3/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
USP2 O75604 1/20 0.39
KDM4E B2RXH2 3/20 0.38
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38
ADORA1 P30542 2/20 0.37
ATM Q13315 1/20 0.37
PKM P14618 1/20 0.37
SERPINE1 P05121 1/20 0.37
HIF1A Q16665 1/20 0.36
TRPV1 Q8NER1 2/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15978945 0.88 MCL1 (0.45) MCL1KMT2AMEN1USP2KDM4E
SCHEMBL15970555 0.87 LIPG (0.44) HDAC1HDAC2HDAC3KMT2AMEN1
SCHEMBL15969863 0.86 MCHR1 (0.41) HDAC1HDAC2MCHR1HDAC3KMT2A
SCHEMBL15970027 0.83 HDAC1 (0.41) HDAC1HDAC2MCHR1HDAC3KMT2A
SCHEMBL15969813 0.83 KMT2A (0.40) MCL1KMT2AMEN1NPC1RAB9A
SCHEMBL15969812 0.83 KMT2A (0.40) MCL1KMT2AMEN1NPC1RAB9A
SCHEMBL15969624 0.79 TRPV1 (0.51) HDAC1HDAC2HDAC3KMT2AMEN1
SCHEMBL15970126 0.77 TRPV1 (0.53) HDAC1HDAC2ADORA1TRPV1
SCHEMBL15969701 0.76 TRPV1 (0.54) HDAC1HDAC2KMT2AMEN1SERPINE1
SCHEMBL15969766 0.74 MMP13 (0.51) KMT2AMEN1NPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2760840-B1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL MYERS SQUIBB CO (US) 2015-08-12 EP claimed
EP-2760840-B1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL MYERS SQUIBB CO (US) 2015-08-12 EP disclosed
EP-2760840-B1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL MYERS SQUIBB CO (US) 2015-08-12 EP disclosed
US-20150105376-A1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL MYERS SQUIBB CO (US) 2015-04-16 US disclosed
US-20150105376-A1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL MYERS SQUIBB CO (US) 2015-04-16 US disclosed
US-8946430-B2 Quinolinone carboxamide inhibitors of endothelial lipase BRISTOL-MYERS SQUIBB COMPANY (US) 2015-02-03 US disclosed
US-8946430-B2 Quinolinone carboxamide inhibitors of endothelial lipase BRISTOL-MYERS SQUIBB COMPANY (US) 2015-02-03 US disclosed
US-20140243314-A1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL-MYERS SQUIBB COMPANY 2014-08-28 US disclosed
US-20140243314-A1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL-MYERS SQUIBB COMPANY 2014-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105376-A1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE LIPG, PNLIP, LPL MCL1 2993/4885HDAC1 244/4885HDAC2 276/4885
US-20140243314-A1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE LIPG, PNLIP, LPL MCL1 2993/4885HDAC1 244/4885HDAC2 276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.